Norman Nagl

Norman Nagl has a diverse work experience in the medical and pharmaceutical field. Norman is currently employed as the Vice President of Medical Affairs at Syndax Pharmaceuticals since January 2024. Prior to this, they worked as the Vice President of Medical Affairs at G1 Therapeutics, Inc. from January 2022 to November 2023. From 2017 to 2020, they served as the Executive Director and Therapeutic Area Lead Oncology at Daiichi Sankyo, Inc. Norman also held various positions at Merck, including Executive Director of International Medical Leader from 2016 to 2017 and Director of Pembrolizumab Global Marketing from 2014 to 2016. Additionally, they worked as the Director of Oncology Medical Strategy at Eisai from 2011 to 2014 and Chief Medical Officer at p-value communications from 2009 to 2011. Norman started their career in Medical Education and Advertising, where they held the roles of Director of Scientific Communications and VP of Medical and Scientific Services from 2004 to 2009. In 2013, Norman became an Adjunct Professor of Genetics at Monmouth University.

Norman Nagl attended Temple University - Lewis Katz School of Medicine from 1999 to 2004, where they obtained a PhD in Molecular Biology and Genetics. Prior to that, they studied at Juniata College from 1995 to 1998 and earned a Bachelor of Science degree in Molecular Biology. There is no information available on their education at AAHS.